Abstract
Neuregulin-1 (NRG-1)/ErbB signaling has an indispensable role in cardiac development and in the maintenance of the structural and functional integrity of the human adult heart in health and disease. Several animal studies have now demonstrated the therapeutic effects of NRG-1 during acute cardiac injury and during chronic heart failure, with improvements in cardiac performance and animal survival. Phase I and II clinical trials for chronic heart failure in humans are now in progress.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Cardiovascular Agents / therapeutic use*
-
Cardiovascular Diseases / drug therapy*
-
Cardiovascular Diseases / metabolism
-
Cardiovascular Diseases / physiopathology
-
Cardiovascular System / drug effects*
-
Cardiovascular System / metabolism
-
Cardiovascular System / physiopathology
-
ErbB Receptors / drug effects
-
ErbB Receptors / metabolism
-
Humans
-
Neuregulin-1 / metabolism
-
Neuregulin-1 / therapeutic use*
-
Receptor, ErbB-2 / drug effects
-
Receptor, ErbB-2 / metabolism
-
Receptor, ErbB-4
-
Recombinant Proteins / therapeutic use
-
Signal Transduction / drug effects
Substances
-
Cardiovascular Agents
-
Neuregulin-1
-
Recombinant Proteins
-
ERBB4 protein, human
-
ErbB Receptors
-
Receptor, ErbB-2
-
Receptor, ErbB-4